Loading…
Jiangsu heparin API producer, one of China's major suppliers of heparin sodium used in blood-thinning drugs worldwide.
Jiangsu heparin API producer, one of China's major suppliers of heparin sodium used in blood-thinning drugs worldwide.
Processes pig-derived raw material, mainly intestinal mucosa, into heparin, so its costs and the price it can charge move with hog supply cycles. Sales abroad depend on overseas regulators approving its plant and drug filings.
In one line: A heparin-focused API exporter.
Moat: narrow (scale, regulatory licence). Scaled porcine-heparin sourcing and processing with multiple export regulatory filings.
Headquarters: Changzhou, China · Employees: 1,038
Size Changzhou Qianhong Bio-Pharma (002550.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 1958th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.45 on 6 Nov 2026.
Performance Over six months the shares fell 7.9%, against -6.2% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 1.5% over the last twelve months (peer median -2.0%); the operating margin is 15.4% (peer median 3.4%).
Valuation It trades at 19.6× forward earnings against a peer median of 19.6× (5th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.51B | CN¥1.56B | CN¥1.51B | CN¥1.80B | CN¥2.29B |
| Revenue growth | — | +3% | -16% | -21% | — |
| Gross profit | CN¥857M | CN¥869M | CN¥789M | CN¥735M | CN¥845M |
| EBITDA | n/a | CN¥498M | CN¥429M | CN¥226M | CN¥291M |
| Net income | CN¥231M | CN¥399M | CN¥356M | CN¥182M | CN¥323M |
| Free cash flow | CN¥351M | CN¥408M | CN¥487M | CN¥429M | -CN¥139M |
| Capital expenditure | CN¥169M | CN¥142M | CN¥90.6M | CN¥100M | CN¥71.0M |
| Total debt | CN¥78.7M | CN¥3.34M | CN¥21.5M | CN¥56.1M | CN¥100M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Changzhou Qianhong Bio-Pharma 002550.SZ | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | $2.15B | -3% | +9% | 14% | 22.8× | 6.1% |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002550.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -4.8% | 9th highest of 21 |
| 6-month return | -7.9% | -6.2% | 11th highest of 21 |
| Distance from 52-week high | -31.7% | -33.3% | 11th highest of 21 |
| Revenue growth (TTM) | -1.5% | -2.0% | 9th highest of 17 |
| Operating margin | 15.4% | 3.4% | 3rd highest of 18 |
| Forward P/E | 19.6× | 19.6× | 5th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 4.5% | 5.8% | 5th least demanding of 10 |
| Growth delivered (Del g) | -1.2% | +5.8% | 4th lowest of 10 |
| Hurdle (Req g minus delivered) | +5.7 pp | -3.3 pp | 2nd most demanding of 10 |
| ROIC minus cost of capital | +8.7 pp | -5.0 pp | highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |